Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Amazon was struggling before mixed second-quarter results, but it has several attractive growth opportunities. Mounting ...

Merck & Co. has become a standout player in the Dow thanks to its steady revenue streams and hedge fund popularity. It ranks ...

We can contribute innovation globally,” Xia says. “I think that's very satisfying.” As director general of the World Health ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Merck & ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for first quarter ...

The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...